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Background
The aim of this study was to characterize the metabolic
abnormalities resulting in low HDL apolipoprotein AI
(HDL-AI) levels in lipodystrophy HIV infected patients
during protease inhibitor therapy.
Methods
Seven HIV infected patients, normolipidemic with no
lipodystrophy (group A) and seven hyperlipidemic with
lipodystrophy (group B) were studied. Patients are on
protease inhibitors since at least six months. Patients
were underwent in vivo kinetics of HDL-AI using a 14 h
primed constant infusion of [5,5,5,2H3] leucine. Kinetic
data were analyzed by monocompartmental model using
SAMII program to drive metabolic parameters (FCR,
Fractional Catabolic Rate, and APR, Absolute Catabolic
Rate).
Results
Subjects in group B showed significantly higher plasma
triglycerides (p < 0.05). HDL cholesterol and apolipopro-
tein AI (apoAI) were significantly (P < 0.05) lower in
group B compared to group A. HDL are more enriched
in triglycerides in group B compared to group A (P <
0.005). Kinetic study showed no change of fractional
catabolic rate between two groups but significantly (P <
0.05) lower APR in group B compared to group A.
Discussion
These results showed that the hypertriglyceridemia and
low HDL level associated with lipodystrophy in HIV
infected patients during treatment is related essentially
to low absolute catabolic rate. As was almost reported,
the HDL enriched in TG are quickly catabolised. In our
patient from group B, although HDL were enriched in
TG their FCR was normal suggesting a primary abnorm-
ality in apoAI synthesis and/or secretion.
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